TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension	Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, hepatocellular carcinoma, liver disorder, portal hypertension	Not yet recruiting	Phase 2	2026-01-20		NCT07350070

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Tongji Hospital	276

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Hepatobiliary and Pancreatic Oncology	Fuzhou	China	1
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University	Nanning	China	1
Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	3
Hubei Province Tahe Hospital	Taihe	China	1
Organ Transplant Department,Qilu Hospital, Cheeloo College of Medicine, Shandong University,	Jinan	China	1
Qingdao University Affiliated Hospital	Qingdao	China	3
Shandong First Medical University Affiliated Provincial Hospital	Jinan	China	1